My personal involvement in hypertension covers about half of the past century, starting just about at the same time when the treatment of hypertension became both effective and practical. Although parenteral drugs had been used to control hypertensive crises starting in 1940, only when hydralazine and rauwolfia became available in 1949 did it become feasible to use oral therapy in large numbers of patients. After the introduction of thiazide diuretics, guanethidine, and methyldopa in the late 1950s, effective control of the common forms of hypertension became practical.
The subsequent addition of beta-blockers, central ␣ 2 -agonists, alpha-blockers, calcium channel blockers, ACE inhibitors, and angiotensin II-receptor blockers brings this therapeutic revolution to its present state.
Perhaps not as dramatic in their impact an antibiotics and antiviral agents, antihypertensive drugs have become the most widely prescribed drugs in most industrialized societies. 1 As reviewed in the previous article, therapeutic trials, mostly randomised and placebo-controlled, have documented the efficacy of these therapies in patients with progressively lower and lower levels of hypertension. Starting with trials in malignant hypertensives in 1958 and proceeding through the present time, we are now approaching the active drug therapy of patients with blood pressures that are below the artificial dividing line of 140/90 mm Hg that has traditionally defined hypertension. More about this later.
The time for acceptance
It has taken about 50 years to document the efficacy of active drug therapy in the largest segment of the hypertensive population-those with blood pressures only slightly above the 140/90 mm Hg level.
On the other hand, it has taken less than 10 years to document the efficacy of the treatment of the mildest form of hypercholesterolaemia. 2 The reason for this different time frame includes a lesson that drug marketers learned from the hypertension area: the need to prove through large, randomised-controlled trials, the ability of their products to reduce morbidity and mortality. Many hypertensive agents were introduced and widely used without such proof, only having fulfilled the regulatory agency's requirements of antihypertensive efficacy and relative safety compared to other approved agents.
The lack of data on morbidity and mortality exposed the most popular class of hypertensive agents, the calcium channel blockers, to a series of inflammatory defamation's. Although these accusations have been largely proved to be groundless, they undermined the confidence that many patients had in their physicians and the confidence that many physicians had in the regulatory process.
As soon as statins became available, morbidity and mortality trials were begun. Therefore, they have been eagerly accepted in much less time than most antihypertensive drugs.
Another difference between antihypertensive drugs and the statins are in their side effect profile. Although the currently available antihypertensives are relatively easy to take, the original choices had many bothersome side effects. Therefore, it is not surprising that their acceptance was less rapid than the amazingly benign statin drugs.
Improved targeting of therapy
As increasingly easy to take antihypertensives became available, randomised controlled trials documented the special benefits of different agents in the large majority of hypertensives who had coexisting, comorbid conditions. [3] [4] [5] In all three of the recently published sets of guidelines, 'compelling' indications for specific drugs target their use (Table 1) . Rather than broad, scatter-shot blasts at the blood pressure, more and more specific, focused indications have been recognised. Thereby, greater benefits have been documented for certain agents in specific circumstances. ACE-inhibitors may be beneficial in chronic renal failure but should only be used with caution. Caution with ACE-inhibitors and AIIantagonists in peripheral vascular disease because of association with renovascular disease. Beta-blockers may worsen heart failure, but in specialist hands may be used to treat heart failure.
Sometimes, surprises come from controlled comparative trials. ACE inhibitors had been widely assumed to be the best drugs for diabetic hypertensives since they were so effective in reducing the proteinuria of diabetic nephropathy. But when an ACE inhibitor was compared to a theoretically less attractive agent, a beta-blocker, in the United Kingdom Prospective Diabetes Study (UKPDS), the betablocker came out slightly better. 7 Similarly, ACE inhibitors may not be so much better than other agents in reducing proteinuria or, more importantly, slowing down the progression of renal damage. 8 These data confirmed the need to go beyond theory and preliminary experience. Only proper comparative trials can document the value of specific agents.
A look at the future
As far as we have come, only one of four or even fewer hypertensives are currently being adequately treated to the level needed to protect them maximally. Obviously, we must do better.
We must, because the burden of hypertension will continually increase as people live longer and become increasingly fat, diabetic, and dyslipidaemic. Here are a few of the ways that may improve our ability to do so.
• Begin lifestyle modifications earlier, well before hypertension surfaces. Obesity can be prevented in childhood, as simply as turning off the TV set and increasing physical activity. However, the social forces are improperly aligned: computer games are more than able to replace TV and walking to school or work has often become physically impossible. Of all the lifestyle changes that can be implemented without individual action, moderation of sodium intake is the easiest, simply by gradual reductions in the amount of salt added to processed foods. Hopefully, the recent documentation that less cardiovascular damage is seen in those who consume less sodium 9 will help remove the cloud that some have placed over population-wide moderation of sodium intake.
• Institute antihypertensive drug therapy sooner, before target organ damage has developed. Proper trials will need to confirm the benefits of earlier therapy at lower levels of blood pressure. The data on those with diabetes and/or renal damage have pointed the way toward much earlier therapy to much lower goals. Moreover, the need to base therapeutic decisions on more than blood pressure levels alone, taking the entire cardiovascular risk profile into account, has been stressed in all recent guidelines. As this need becomes more widely perceived, earlier therapy for those at higher risk even with relatively little hypertension will be provided.
• Target therapy more precisely. As more and more comparative trials are reported, sharper distinctions about the relative value of specific agents in specific patients will become obvious.
• Use drugs that are more user friendly. The calls for long-acting, once-a-day formulations and for appropriate low-dose combinations are useful beginnings in this direction. As even more benign agents are introduced, it should be easier to keep patients on therapy.
• Involve the patient in the process. Home blood pressure recordings should become routine, not only because they give a more accurate portrayal of the hypertensive process, but also because they encourage patients to continue therapy. As confidence grows among physicians about their val-idity, they will become as widely available as thermometers-and a lot more useful.
A longer view
I hesitate to foretell the distant future. Defective genes may be replaced; implanted drug delivery systems may provide just enough medication as needed to keep the constantly monitored blood pressure at exactly the desired level; neurovascular decompression may actually prove to be more than a neurosurgeon's pipe dream.
We have enough to do in the foreseeable future. If what we now know is effectively implemented, the future will be far better for the millions of hypertensives who are now not being protected.
